Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | CAR-T cell approaches to combat an immunosuppressive tumor microenvironment

Yufei Wang, PhD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of how studies are using different checkpoint inhibitor blockades for CAR-T cell therapies. For example, utilising anti-VEGFR to destroy tumor vasculature and combat an immunosuppressive tumor microenvironment. This interview took place at the American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans, LA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.